Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Vistin Pharma ASA : Approval and publication of prospectus

Vistin Pharma ASA
Posted on: 09 May 18

This announcement is not for release, publication or distribution (directly or indirectly) in or to the United States, Canada, Australia or Japan. It is not an offer of securities for sale in or into the United States, Canada, Australia, the Hong Kong Special Administrative Region of the People's Republic of China, South Africa or Japan.

Reference is made to Vistin Pharma ASA's (" Vistin Pharma " or the " Company ") stock exchange notice dated 22 March 2018 relating to the completed NOK 300 million private placement (the " Private Placement ") and the proposed NOK 50 million subsequent repair issue (the "Subsequent Repair Issue" ). Further reference is made to the Company's announcements on 8 May 2018 and 9 May 2018 regarding the approval by the annual general meeting of the Private Placement and the Subsequent Repair Issue, and the increase of the share capital related to the Private Placement.

The Financial Supervisory Authority of Norway has approved the prospectus dated 9 May 2018 (the " Prospectus ") which has been prepared in connection with the listing of up to 31,250,001 new shares on Oslo Axess, of which 26,785,715 shares (the "Private Placement Shares" ) have been issued in connection with the Private Placement and up to 4,464,286 new shares that will be offered and issued in connection with the Subsequent Repair Issue.

The Private Placement Shares will be settled towards the investors that were allocated shares in the Private Placement on or about 14 May 2018 through delivery versus payment.

Shareholders in the Company as of 22 March 2018, as registered in the VPS on 26 March 2018, who were not allocated Offer Shares in the Private Placement and who are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action, will be eligible to participate in the Subsequent Repair Issue and will be allocated subscription rights. The subscription rights will not be listed and over-subscription and subscription without subscription rights will be allowed in the Subsequent Repair Issue. The subscription price in the Subsequent Repair Issue will be the same as in the Private Placement, i.e. NOK 11.20 per share.

The subscription period for the Subsequent Repair Issue will commence on 09:00 CET on 14 May 2018 and expire on 25 May 2018 at 16:30 CET.

A stock exchange notice with further information on the Subsequent Repair Issue will be published prior to commencement of the subscription period.

The Prospectus will, subject to regulatory restrictions in certain jurisdictions, be available at the following website:

Hard copies of the Prospectus may be obtained free of charge at the offices of Vistin Pharma ASA at Østensjøveien 27, 0661 Oslo, Norway.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Gunnar Manum
+47 951 79 190

This announcement is not and does not form a part of any offer for sale of any securities, and is not for release, publication or distribution, directly or indirectly, in the United States, or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. Securities may not be sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended. Vistin Pharma ASA does not intend to register its securities in the United States. The distribution of this announcement into jurisdictions other than Norway may be restricted by law. Persons into whose possession this announcement comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. This announcement has not been approved by any regulatory authority.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Vistin Pharma ASA via GlobeNewswire

Last updated on: 10/05/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.